In the last 12 months, insiders at OCULAR THERAPEUTIX, INC ($OCUL) filed 145 transactions with the SEC: 3 open-market purchases totaling $7,530,954 and 53 sales totaling $4,788,189. Net insider sentiment: net buying.
OCULAR THERAPEUTIX, INC operates in the Pharmaceutical preparations industry (Life sciences sector).
Most Active Insiders
- SUMMER ROAD LLC (Not found) — 1 transaction totaling $7,000,000
- Dugel Pravin (See Remarks) — 19 transactions totaling $2,588,691
- LINDSTROM RICHARD L MD (Director) — 10 transactions totaling $797,612
- Heier Jeffrey S. (Chief Scientific Officer) — 11 transactions totaling $289,202
- Saroj Namrata (Chief Business Officer) — 3 transactions totaling $277,790
View all SEC Filings for OCULAR THERAPEUTIX, INC (OCUL).
Set Up your own filters →Recent Insider Transactions
| Transaction Date | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 23, 2026 | Kaiser Peter | Chief Development Officer | S | Common Stock | 2810 | $8.28 | 269,108.0000 | 187,241,483 | 1.03% | 0.00% |
| Feb. 23, 2026 | Dugel Pravin | See Remarks | S | Common Stock | 20056 | $8.28 | 3,313,137.0000 | 187,241,483 | 0.60% | 0.01% |
| Feb. 23, 2026 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1759 | $8.28 | 330,653.0000 | 187,241,483 | 0.53% | 0.00% |
| Feb. 23, 2026 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 3057 | $8.28 | 323,368.0000 | 187,241,483 | 0.94% | 0.00% |
| Feb. 20, 2026 | Waheed Nadia | Chief Medical Officer | S | Common Stock | 3510 | $7.74 | 314,907.0000 | 187,241,483 | 1.10% | 0.00% |
| Feb. 20, 2026 | LINDSTROM RICHARD L MD | Director | P | Common Stock | 60229 | $7.66 | 246,933.0000 | 187,241,483 | 32.26% | 0.03% |
| Feb. 12, 2026 | Notman Donald | Chief Operating Officer | S | Common Stock | 11446 | $9.04 | 366,356.0000 | 187,241,483 | 3.03% | 0.01% |
| Feb. 12, 2026 | Dugel Pravin | See Remarks | S | Common Stock | 124882 | $9.04 | 3,333,193.0000 | 187,241,483 | 3.61% | 0.07% |
| Feb. 12, 2026 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 10348 | $9.04 | 332,412.0000 | 187,241,483 | 3.02% | 0.01% |
| Feb. 12, 2026 | Waheed Nadia | Chief Medical Officer | S | Common Stock | 7863 | $9.04 | 318,417.0000 | 187,241,483 | 2.41% | 0.00% |
| Feb. 4, 2026 | Notman Donald | Chief Operating Officer | S | Common Stock | 6035 | $8.54 | 377,802.0000 | 187,241,483 | 1.57% | 0.00% |
| Feb. 2, 2026 | Notman Donald | Chief Operating Officer | S | Common Stock | 5455 | $9.14 | 383,837.0000 | 187,241,483 | 1.40% | 0.00% |
| Jan. 21, 2026 | Robinson David Wayne | Global CCO | A | Stock Option (Right to Buy) | 416000 | $0.00 | 416,000.0000 | 187,241,483 | 9999.99% | 0.22% |
| Jan. 21, 2026 | Robinson David Wayne | Global CCO | A | Common Stock | 136000 | $0.00 | 136,000.0000 | 187,241,483 | 9999.99% | 0.07% |
| Jan. 20, 2026 | Robins Jason Shand | Interim CFO | A | Stock Option (Right to Buy) | 33000 | $0.00 | 33,000.0000 | 187,241,483 | 9999.99% | 0.02% |
| Jan. 2, 2026 | Heier Jeffrey S. | Chief Scientific Officer | A | Common Stock | 79112 | $0.00 | 326,425.0000 | 187,241,483 | 31.99% | 0.04% |
| Jan. 2, 2026 | Anderman Todd | Chief Legal Officer | A | Common Stock | 64900 | $0.00 | 152,468.0000 | 187,241,483 | 74.11% | 0.03% |
| Jan. 2, 2026 | Anderman Todd | Chief Legal Officer | A | Stock Option (Right to Buy) | 197650 | $0.00 | 197,650.0000 | 187,241,483 | 9999.99% | 0.11% |
| Jan. 2, 2026 | Meyers Steve Lawrence | Chief Commercial Officer | A | Common Stock | 64900 | $0.00 | 217,628.0000 | 187,241,483 | 42.49% | 0.03% |
| Jan. 2, 2026 | Meyers Steve Lawrence | Chief Commercial Officer | A | Stock Option (Right to Buy) | 197650 | $0.00 | 197,650.0000 | 187,241,483 | 9999.99% | 0.11% |
| Jan. 2, 2026 | Nayak Sanjay | Chief Strategy Officer | A | Common Stock | 64900 | $0.00 | 342,760.0000 | 187,241,483 | 23.36% | 0.03% |
| Jan. 2, 2026 | Nayak Sanjay | Chief Strategy Officer | A | Stock Option (Right to Buy) | 197650 | $0.00 | 197,650.0000 | 187,241,483 | 9999.99% | 0.11% |
| Jan. 2, 2026 | Kaiser Peter | Chief Development Officer | A | Common Stock | 79112 | $0.00 | 271,918.0000 | 187,241,483 | 41.03% | 0.04% |
| Jan. 2, 2026 | Kaiser Peter | Chief Development Officer | A | Stock Option (Right to Buy) | 240932 | $0.00 | 240,932.0000 | 187,241,483 | 9999.99% | 0.13% |
| Jan. 2, 2026 | Saroj Namrata | Chief Business Officer | A | Common Stock | 79112 | $0.00 | 254,620.0000 | 187,241,483 | 45.08% | 0.04% |
| Jan. 2, 2026 | Saroj Namrata | Chief Business Officer | A | Stock Option (Right to Buy) | 240932 | $0.00 | 240,932.0000 | 187,241,483 | 9999.99% | 0.13% |
| Jan. 2, 2026 | Waheed Nadia | Chief Medical Officer | A | Common Stock | 79112 | $0.00 | 326,280.0000 | 187,241,483 | 32.01% | 0.04% |
| Jan. 2, 2026 | Notman Donald | See Remarks | A | Stock Option (Right to Buy) | 240932 | $0.00 | 240,932.0000 | 187,241,483 | 9999.99% | 0.13% |
| Jan. 2, 2026 | Notman Donald | See Remarks | A | Common Stock | 79112 | $0.00 | 389,292.0000 | 187,241,483 | 25.51% | 0.04% |
| Jan. 2, 2026 | Heier Jeffrey S. | Chief Scientific Officer | A | Stock Option (Right to Buy) | 240932 | $0.00 | 240,932.0000 | 187,241,483 | 9999.99% | 0.13% |
| Jan. 2, 2026 | Waheed Nadia | Chief Medical Officer | A | Stock Option (Right to Buy) | 240932 | $0.00 | 240,932.0000 | 187,241,483 | 9999.99% | 0.13% |
| Nov. 24, 2025 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 3469 | $12.04 | 245,940.0000 | 183,919,808 | 1.39% | 0.00% |
| Nov. 24, 2025 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1878 | $12.04 | 277,860.0000 | 183,919,808 | 0.67% | 0.00% |
| Nov. 26, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 49754 | $0.00 | 3,458,075.0000 | 183,919,808 | 1.42% | 0.03% |
| Nov. 24, 2025 | Dugel Pravin | See Remarks | S | Common Stock | 19530 | $12.04 | 3,458,075.0000 | 183,919,808 | 0.56% | 0.01% |
| Nov. 24, 2025 | Kaiser Peter | Chief Development Officer | S | Common Stock | 3007 | $12.02 | 191,433.0000 | 183,919,808 | 1.55% | 0.00% |
| Nov. 26, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 49754 | $0.00 | 3,458,075.0000 | 183,919,808 | 1.46% | 0.03% |
| Nov. 5, 2025 | Saroj Namrata | Chief Business Officer | S | Common Stock | 25865 | $10.74 | 174,135.0000 | 183,919,808 | 12.93% | 0.01% |
| Oct. 8, 2025 | Anderman Todd | Chief Legal Officer | S | Common Stock | 11132 | $12.34 | 87,568.0000 | 183,919,808 | 11.28% | 0.01% |
| Oct. 2, 2025 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 10502 | $11.04 | 249,409.0000 | 183,919,808 | 4.04% | 0.01% |
| Oct. 2, 2025 | Kaiser Peter | Chief Development Officer | S | Common Stock | 9653 | $11.03 | 194,440.0000 | 183,919,808 | 4.73% | 0.01% |
| Sept. 9, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 49754 | $0.00 | 3,477,605.0000 | 172,594,662 | 1.41% | 0.03% |
| Sept. 9, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 49754 | $0.00 | 3,477,605.0000 | 172,594,662 | 1.45% | 0.03% |
| Sept. 2, 2025 | Notman Donald | See Remarks | S | Common Stock | 1066 | $12.43 | 308,807.0000 | 172,594,662 | 0.34% | 0.00% |
| Aug. 25, 2025 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1885 | $12.04 | 279,738.0000 | 172,594,662 | 0.67% | 0.00% |
| Aug. 25, 2025 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 3063 | $12.04 | 259,911.0000 | 172,594,662 | 1.16% | 0.00% |
| Aug. 25, 2025 | Dugel Pravin | See Remarks | S | Common Stock | 21494 | $12.04 | 3,477,605.0000 | 172,594,662 | 0.61% | 0.01% |
| Aug. 25, 2025 | Kaiser Peter | Chief Development Officer | S | Common Stock | 3011 | $12.04 | 204,093.0000 | 172,594,662 | 1.45% | 0.00% |
| Aug. 12, 2025 | Waheed Nadia | Chief Medical Officer | A | Common Stock | 40363 | $0.00 | 247,168.0000 | 172,594,662 | 19.52% | 0.02% |
| Aug. 12, 2025 | Waheed Nadia | Chief Medical Officer | A | Stock Option (Right to Buy) | 122923 | $0.00 | 122,923.0000 | 172,594,662 | 9999.99% | 0.07% |
| June 12, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 50029 | $0.00 | 3,499,099.0000 | 169,396,989 | 1.41% | 0.03% |
| April 28, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 200332 | $0.00 | 3,549,128.0000 | 169,396,989 | 5.34% | 0.12% |
| Aug. 11, 2025 | Dugel Pravin | See Remarks | G | Common Stock | 250361 | $0.00 | 3,499,099.0000 | 172,594,662 | 7.71% | 0.15% |
| June 11, 2025 | Graves Adrienne L | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | RAINES MERILEE | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | LINDSTROM RICHARD L MD | Director | A | Common Stock | 14000 | $0.00 | 186,704.0000 | 169,396,989 | 8.11% | 0.01% |
| June 11, 2025 | LINDSTROM RICHARD L MD | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | Williams Leslie J. | Director | A | Common Stock | 14000 | $0.00 | 51,433.0000 | 169,396,989 | 37.40% | 0.01% |
| June 11, 2025 | Williams Leslie J. | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | Warden Charles M | Director | A | Common Stock | 14000 | $0.00 | 86,464.0000 | 169,396,989 | 19.32% | 0.01% |
| June 11, 2025 | Warden Charles M | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | Graves Adrienne L | Director | A | Common Stock | 14000 | $0.00 | 50,000.0000 | 169,396,989 | 38.89% | 0.01% |
| June 11, 2025 | Hong Seung Suh | Director | A | Stock Option (Right to Buy) | 44000 | $0.00 | 44,000.0000 | 169,396,989 | 9999.99% | 0.03% |
| June 11, 2025 | RAINES MERILEE | Director | A | Common Stock | 14000 | $0.00 | 46,933.0000 | 169,396,989 | 42.51% | 0.01% |
| June 11, 2025 | Hong Seung Suh | Director | A | Common Stock | 14000 | $0.00 | 46,933.0000 | 169,396,989 | 42.51% | 0.01% |
| June 11, 2025 | Dugel Pravin | See Remarks | A | Performance Stock Option (Right to Buy) | 2750000 | $0.00 | 2,750,000.0000 | 169,396,989 | 9999.99% | 1.62% |
| June 2, 2025 | Waheed Nadia | Chief Medical Officer | S | Common Stock | 13861 | $8.05 | 206,805.0000 | 169,396,989 | 6.28% | 0.01% |
| May 23, 2025 | Dugel Pravin | See Remarks | S | Common Stock | 21219 | $7.18 | 3,499,099.0000 | 169,396,989 | 0.60% | 0.01% |
| May 23, 2025 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1862 | $7.17 | 281,623.0000 | 169,396,989 | 0.66% | 0.00% |
| May 23, 2025 | Kaiser Peter | Chief Development Officer | S | Common Stock | 2974 | $7.17 | 207,104.0000 | 169,396,989 | 1.42% | 0.00% |
| May 23, 2025 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 3024 | $7.18 | 262,974.0000 | 169,396,989 | 1.14% | 0.00% |
| May 8, 2025 | LINDSTROM RICHARD L MD | Director | P | Common Stock | 10000 | $6.96 | 172,704.0000 | 169,396,989 | 6.15% | 0.01% |
| Feb. 24, 2025 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1895 | $6.84 | 283,485.0000 | 158,265,162 | 0.66% | 0.00% |
| Feb. 24, 2025 | Kaiser Peter | Chief Development Officer | S | Common Stock | 3009 | $6.87 | 210,078.0000 | 158,265,162 | 1.41% | 0.00% |
| Feb. 24, 2025 | Dugel Pravin | See Remarks | S | Common Stock | 21475 | $6.87 | 3,520,318.0000 | 158,265,162 | 0.61% | 0.01% |
| Feb. 24, 2025 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 3061 | $6.87 | 265,998.0000 | 158,265,162 | 1.14% | 0.00% |
| Feb. 11, 2025 | Waheed Nadia | Chief Medical Officer | A | Stock Option (Right to Buy) | 237000 | $0.00 | 237,000.0000 | 158,265,162 | 9999.99% | 0.15% |
| Feb. 11, 2025 | Notman Donald | See Remarks | A | Common Stock | 115000 | $0.00 | 308,444.0000 | 158,265,162 | 59.45% | 0.07% |
| Feb. 11, 2025 | Notman Donald | See Remarks | A | Stock Option (Right to Buy) | 344115 | $0.00 | 344,115.0000 | 158,265,162 | 9999.99% | 0.22% |
| Feb. 11, 2025 | Nayak Sanjay | Chief Strategy Officer | A | Common Stock | 111000 | $0.00 | 285,380.0000 | 158,265,162 | 63.65% | 0.07% |
| Feb. 11, 2025 | Nayak Sanjay | Chief Strategy Officer | A | Stock Option (Right to Buy) | 334000 | $0.00 | 334,000.0000 | 158,265,162 | 9999.99% | 0.21% |
| Feb. 11, 2025 | Dugel Pravin | See Remarks | A | Common Stock | 1250000 | $0.00 | 2,041,793.0000 | 158,265,162 | 157.87% | 0.79% |
| Feb. 11, 2025 | Dugel Pravin | See Remarks | A | Common Stock | 1500000 | $0.00 | 3,541,793.0000 | 158,265,162 | 73.46% | 0.95% |
| Feb. 11, 2025 | Waheed Nadia | Chief Medical Officer | A | Common Stock | 79000 | $0.00 | 220,666.0000 | 158,265,162 | 55.76% | 0.05% |
| Jan. 31, 2025 | Notman Donald | See Remarks | S | Common Stock | 6301 | $7.84 | 204,563.0000 | 158,265,162 | 2.99% | 0.00% |
| Feb. 4, 2025 | Notman Donald | See Remarks | S | Common Stock | 11119 | $7.81 | 193,444.0000 | 158,265,162 | 5.44% | 0.01% |
| Nov. 25, 2024 | Dugel Pravin | See Remarks | S | Common Stock | 20680 | $9.01 | 791,793.0000 | 166,992,735 | 2.55% | 0.01% |
| Nov. 25, 2024 | Heier Jeffrey S. | Chief Scientific Officer | S | Common Stock | 2948 | $9.01 | 269,059.0000 | 166,992,735 | 1.08% | 0.00% |
| Nov. 25, 2024 | Kaiser Peter | Chief Development Officer | S | Common Stock | 2897 | $9.01 | 213,087.0000 | 166,992,735 | 1.34% | 0.00% |
| Nov. 25, 2024 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1814 | $9.00 | 174,380.0000 | 166,992,735 | 1.03% | 0.00% |
| Oct. 7, 2024 | Anderman Todd | Chief Legal Officer | A | Common Stock | 98700 | $0.00 | 98,700.0000 | 166,992,735 | 9999.99% | 0.06% |
| Oct. 7, 2024 | Anderman Todd | Chief Legal Officer | A | Stock Option (Right to Buy) | 296500 | $0.00 | 296,500.0000 | 166,992,735 | 9999.99% | 0.18% |
| Oct. 2, 2024 | Heier Jeffrey S. | Chief Scientific Officer | A | Common Stock | 100000 | $0.00 | 272,007.0000 | 166,992,735 | 58.14% | 0.06% |
| Oct. 2, 2024 | Kaiser Peter | Chief Development Officer | A | Common Stock | 100000 | $0.00 | 215,984.0000 | 166,992,735 | 86.22% | 0.06% |
| Oct. 2, 2024 | Kaiser Peter | Chief Development Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 166,992,735 | 9999.99% | 0.12% |
| Oct. 2, 2024 | Heier Jeffrey S. | Chief Scientific Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 166,992,735 | 9999.99% | 0.12% |
| Aug. 29, 2024 | Notman Donald | See Remarks | A | Stock Option (Right to Buy) | 33602 | $0.00 | 33,602.0000 | 165,824,778 | 9999.99% | 0.02% |
| Aug. 29, 2024 | Notman Donald | See Remarks | A | Common Stock | 11034 | $0.00 | 208,988.0000 | 165,824,778 | 5.57% | 0.01% |
| Aug. 23, 2024 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 1832 | $9.02 | 176,194.0000 | 165,824,778 | 1.03% | 0.00% |
| Aug. 23, 2024 | Dugel Pravin | See Remarks | S | Common Stock | 20880 | $9.02 | 812,473.0000 | 165,824,778 | 2.51% | 0.01% |
| July 24, 2024 | LINDSTROM RICHARD L MD | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| July 24, 2024 | Graves Adrienne L | Director | A | Common Stock | 12000 | $0.00 | 36,000.0000 | 165,824,778 | 50.00% | 0.01% |
| July 24, 2024 | Warden Charles M | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| July 24, 2024 | Warden Charles M | Director | A | Common Stock | 12000 | $0.00 | 72,464.0000 | 165,824,778 | 19.85% | 0.01% |
| July 24, 2024 | Williams Leslie J. | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| July 24, 2024 | Williams Leslie J. | Director | A | Common Stock | 12000 | $0.00 | 37,433.0000 | 165,824,778 | 47.18% | 0.01% |
| July 24, 2024 | RAINES MERILEE | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| July 24, 2024 | RAINES MERILEE | Director | A | Common Stock | 12000 | $0.00 | 32,933.0000 | 165,824,778 | 57.33% | 0.01% |
| July 24, 2024 | Hong Seung Suh | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| July 24, 2024 | Hong Seung Suh | Director | A | Common Stock | 12000 | $0.00 | 32,933.0000 | 165,824,778 | 57.33% | 0.01% |
| July 24, 2024 | Graves Adrienne L | Director | A | Stock Option (Right to Buy) | 36000 | $0.00 | 36,000.0000 | 165,824,778 | 9999.99% | 0.02% |
| Feb. 27, 2024 | LINDSTROM RICHARD L MD | Director | M | Stock Option (Right to Buy) | 11363 | $0.00 | 0.0000 | 85,596,594 | 100.00% | 0.01% |
| Feb. 27, 2024 | LINDSTROM RICHARD L MD | Director | M | Stock Option (Right to Buy) | 18939 | $0.00 | 0.0000 | 85,596,594 | 100.00% | 0.02% |
| July 24, 2024 | LINDSTROM RICHARD L MD | Director | A | Common Stock | 12000 | $0.00 | 162,704.0000 | 165,824,778 | 7.96% | 0.01% |
| Feb. 27, 2024 | LINDSTROM RICHARD L MD | Director | M | Common Stock | 11363 | $8.80 | 150,704.0000 | 85,596,594 | 8.15% | 0.01% |
| Feb. 27, 2024 | LINDSTROM RICHARD L MD | Director | M | Common Stock | 18939 | $8.80 | 139,341.0000 | 85,596,594 | 15.73% | 0.02% |
| June 1, 2024 | Waheed Nadia | Chief Medical Officer | A | Stock Option (Right to Buy) | 425000 | $0.00 | 425,000.0000 | 132,021,945 | 9999.99% | 0.32% |
| June 1, 2024 | Waheed Nadia | Chief Medical Officer | A | Common Stock | 141666 | $0.00 | 141,666.0000 | 132,021,945 | 9999.99% | 0.11% |
| May 23, 2024 | Nayak Sanjay | Chief Strategy Officer | S | Common Stock | 2274 | $5.84 | 178,026.0000 | 132,021,945 | 1.26% | 0.00% |
| May 23, 2024 | Dugel Pravin | See Remarks | S | Common Stock | 21626 | $5.79 | 833,353.0000 | 132,021,945 | 2.53% | 0.02% |
| Feb. 26, 2024 | SUMMER ROAD LLC | Not found | P | Common Stock, $0.0001 par value per share | 930851 | $7.52 | 8,591,401.0000 | 85,596,594 | 12.15% | 1.09% |
| Feb. 22, 2024 | Nayak Sanjay | Chief Strategy Officer | A | Stock Option (Right to Buy) | 244550 | $0.00 | 244,550.0000 | 85,596,594 | 9999.99% | 0.29% |
| Feb. 22, 2024 | Nayak Sanjay | Chief Strategy Officer | A | Common Stock | 80300 | $0.00 | 180,300.0000 | 85,596,594 | 80.30% | 0.09% |
| Feb. 22, 2024 | Dugel Pravin | Executive Chairman | A | Stock Option (Right to Buy) | 1282469 | $0.00 | 1,282,469.0000 | 85,596,594 | 9999.99% | 1.50% |
| Feb. 22, 2024 | Dugel Pravin | Executive Chairman | A | Common Stock | 854979 | $0.00 | 854,979.0000 | 85,596,594 | 9999.99% | 1.00% |
| Feb. 3, 2024 | Ozden Rabia Gurses | Chief Medical Officer | A | Common Stock | 66633 | $0.00 | 159,400.0000 | 85,596,594 | 71.83% | 0.08% |
| Feb. 5, 2024 | Strassburger Philip C. | General Counsel | S | Common Stock | 6029 | $4.86 | 161,493.0000 | 85,596,594 | 3.88% | 0.01% |
| Feb. 3, 2024 | Strassburger Philip C. | General Counsel | A | Common Stock | 58304 | $0.00 | 167,522.0000 | 85,596,594 | 53.38% | 0.07% |
| Feb. 3, 2024 | White Christopher G | Chief Business Officer | A | Stock Option (Right to Buy) | 120000 | $0.00 | 120,000.0000 | 85,596,594 | 9999.99% | 0.14% |
| Feb. 5, 2024 | White Christopher G | Chief Business Officer | S | Common Stock | 5910 | $4.86 | 123,689.0000 | 85,596,594 | 5.02% | 0.01% |
| Feb. 3, 2024 | White Christopher G | Chief Business Officer | A | Common Stock | 39980 | $0.00 | 129,599.0000 | 85,596,594 | 44.61% | 0.05% |
| Feb. 3, 2024 | Strassburger Philip C. | General Counsel | A | Stock Option (Right to Buy) | 175000 | $0.00 | 175,000.0000 | 85,596,594 | 9999.99% | 0.20% |
| Feb. 3, 2024 | Mattessich Antony C. | President and CEO | A | Stock Option (Right to Buy) | 549400 | $0.00 | 549,400.0000 | 85,596,594 | 9999.99% | 0.64% |
| Feb. 5, 2024 | Mattessich Antony C. | President and CEO | S | Common Stock | 19642 | $4.86 | 595,201.0000 | 85,596,594 | 3.41% | 0.02% |
| Feb. 3, 2024 | Mattessich Antony C. | President and CEO | A | Common Stock | 180400 | $0.00 | 614,843.0000 | 85,596,594 | 41.52% | 0.21% |
| Feb. 3, 2024 | Notman Donald | Chief Financial Officer | A | Stock Option (Right to Buy) | 185000 | $0.00 | 185,000.0000 | 85,596,594 | 9999.99% | 0.22% |
| Feb. 5, 2024 | Notman Donald | Chief Financial Officer | S | Common Stock | 6212 | $4.86 | 195,356.0000 | 85,596,594 | 3.28% | 0.01% |
| Feb. 3, 2024 | Notman Donald | Chief Financial Officer | A | Common Stock | 61636 | $0.00 | 201,568.0000 | 85,596,594 | 44.05% | 0.07% |
| Feb. 3, 2024 | Ozden Rabia Gurses | Chief Medical Officer | A | Stock Option (Right to Buy) | 200000 | $0.00 | 200,000.0000 | 85,596,594 | 9999.99% | 0.23% |
| Feb. 5, 2024 | Ozden Rabia Gurses | Chief Medical Officer | S | Common Stock | 6346 | $4.86 | 153,054.0000 | 85,596,594 | 4.33% | 0.01% |
| Jan. 31, 2024 | Mattessich Antony C. | President and CEO | S | Common Stock | 18338 | $4.95 | 434,443.0000 | 85,596,594 | 4.05% | 0.02% |
| Jan. 31, 2024 | Notman Donald | Chief Financial Officer | S | Common Stock | 6433 | $4.95 | 139,932.0000 | 85,596,594 | 4.40% | 0.01% |
| Jan. 31, 2024 | Ozden Rabia Gurses | Chief Medical Officer | S | Common Stock | 7764 | $4.95 | 92,767.0000 | 85,596,594 | 7.72% | 0.01% |
| Jan. 31, 2024 | Strassburger Philip C. | General Counsel | S | Common Stock | 6831 | $4.95 | 109,218.0000 | 85,596,594 | 5.89% | 0.01% |
| Jan. 31, 2024 | White Christopher G | Chief Business Officer | S | Common Stock | 5147 | $4.95 | 89,619.0000 | 85,596,594 | 5.43% | 0.01% |